Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG vs Placebo in Myasthenia Gravis
NCT00306033Phase 3Completed
- Sponsor
- University Health Network
- Start
- Mar 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Intravenous Immunoglobulin with Placebo (2 arms). Primary endpoint: Quantitative Myasthenia Gravis Score for Disease Severity at 4 weeks. Started Mar 2004; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT00306033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00306033.